What We're Reading: Page 393
Industry reads hand-picked by our editors
Nov 06, 2014
-
Journal of Acquired Immune Deficiency Syndrome
Innovation in fixed-dose combos: HIV/AIDS therapeutics edition
-
-
-
Lundbeck's schizophrenia drug wallops competition in novel head-to-head trial
-
-
-
-
Allergan-Valeant standoff rages on as Allergan loses in court
-
Regeneron posts solid Q3 on Eylea strength
-
Some payments exempt from Sunshine Act pharma database reporting
Nov 05, 2014
-
RAND study: Biosimilars could save US $44 billion in 10 years
-
-
One-fifth of all drug sales in 2020 could be for pricey, specialty orphan meds
-
-
India-based Wockhardt's profits plummet as it faces continued FDA export ban
-
-
Diagnostics giant LabCorp buys CRO Covance for $6.1 billion
-
-
-
BMS gets heat from advocates over pricing plan for its hep C drug
Nov 04, 2014
-
Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug
-
-
Feds probe whether US officials engaged in insider trading over Dendreon drug
-
-
Most UK diabetes patients fall short of evidence-based treatment goals
-
-
FDA panel endorses approval of Daaichi's blood clot, stroke drug
-
-
Uh-oh: 2/3 of UK docs defying new statin guidelines
-
Nov 03, 2014
Oct 31, 2014
Oct 30, 2014
Oct 29, 2014
-
Novartis smashes in Q3 as earnings soar 45%
-
-
Roche to spend $3.2B on massive R&D cluster in Basel
-
-
-
-
-
Novartis sells off flu vaccines business to CSL for $275 million
-
Sarepta's mega-orphan Duchenne's drug faces more roadblocks
-
Pfizer pulls the plug on pain deal with Pain Therapeutics
Previous
